Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

NCT04616963 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Hiv
Hormone Therapy

Interventions

DRUG: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
DRUG: Emtricitabine Tenofovir Alafenamide 200/25 mg

Sponsor

University of California, San Diego